Stocks
Allogene Therapeutics (ALLO) EBITDA margin US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -441.0% | -138 045% | -316 098% | -625 519% | ||||
| Changes by years, y/y, % | -137 604pp | -178 053pp | +2 577.3% | ||||||
Allogene Therapeutics. EBITDA margin, %
Allogene Therapeutics. EBITDA margin, changes, pp
Allogene Therapeutics (ALLO) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| EBITDA margin, % | ? | -190 519% | -174 716% | -138 147% | -325 962% | -299 768% | -625 519% | |
| Changes by years, y/y, % | -65 437pp | -89 926pp | +22 321pp | -120 911pp | -109 249pp | |||
| Changes by quarters, q/q, % | +14 532pp | +15 803pp | +36 569pp | -187 815pp | +26 194pp | |||
